CRISPR Therapeutics Priced, Nasdaq: CRSP

Preclinical biotech developing therapies based on CRISPR/Cas9 gene editing.

Industry: Health Care

Latest Trade: $16.64 0.00 (0.0%)

First Day Return: +0.6%

Return from IPO: +18.9%

Industry: Health Care

We are a leading gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The application of CRISPR/Cas9 for gene editing was co-invented by one of our scientific founders, Dr. Emmanuelle Charpentier who, along with her collaborators, published work elucidating how CRISPR/Cas9, a naturally occurring viral defense mechanism found in bacteria, can be adapted for use in gene editing. We are applying this technology to treat a broad set of rare and common diseases by disrupting, correcting or regulating the disease related genes. We believe that our scientific expertise, together with our approach, may enable an entirely new class of highly active and potentially curative treatments for patients for whom current biopharmaceutical approaches have had limited success.
more less
IPO News for CRISPR Therapeutics
more
IPO Data
IPO File Date 09/09/2016
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 4.0
Deal Size ($mm) $56
IPO Data
IPO Date 10/18/2016
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 4.0
Deal Size ($mm) $56
Underwriters
more
Company Data
Headquarters Basel, Switzerland
Founded 2013
Employees 77
Website www.crisprtx.com